TELA Bio (NASDAQ:TELA) Issues Earnings Results

TELA Bio (NASDAQ:TELA) announced its quarterly earnings data on Tuesday. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.07), Zacks reports. The company had revenue of $19.06 million during the quarter, compared to analyst estimates of $18.60 million. TELA Bio had a negative net margin of 49.30% and a negative return on equity of 688.50%.

Here are the key takeaways from TELA Bio’s conference call:

• Management said the U.S. commercial reset is showing early proof points, with the field force now fully staffed and new hires ramping toward expected productivity inflection points in the second half of 2026.
• TELA launched OviTex LTR in the U.S., a fully resorbable tissue-based hernia repair option, and said early surgeon feedback has been overwhelmingly positive. The company believes it broadens the portfolio and could help attract new surgeons.
• International momentum was strong, with Europe revenue up 41% year over year, led by the U.K. and supported by validation from the NHS supply chain value-based procurement evaluation.
• First-quarter revenue rose 3% to $19.1 million, while gross margin was 66% and operating loss was flat year over year at $10.5 million. The company reiterated full-year 2026 guidance for at least 8% revenue growth and Q2 revenue of about $20 million.
• OviTex PRS revenue was essentially flat year over year, and management said utilization dipped because several high-volume implanters were unavailable. The company is trying to reduce this concentration risk by training more surgeons per account.

TELA Bio Price Performance

Shares of TELA stock traded down $0.02 on Thursday, hitting $0.95. 16,163 shares of the company’s stock were exchanged, compared to its average volume of 199,932. The company has a 50 day moving average of $0.76 and a 200 day moving average of $0.95. The stock has a market cap of $42.31 million, a P/E ratio of -1.20 and a beta of 1.30. The company has a debt-to-equity ratio of 8.82, a current ratio of 4.20 and a quick ratio of 3.59. TELA Bio has a 12 month low of $0.50 and a 12 month high of $2.20.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TELA. Canaccord Genuity Group decreased their price target on TELA Bio from $4.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, March 25th. Citizens Jmp reduced their price objective on shares of TELA Bio from $5.00 to $3.00 and set a “market outperform” rating on the stock in a research note on Friday, March 27th. Piper Sandler dropped their target price on shares of TELA Bio from $1.25 to $1.00 and set a “neutral” rating for the company in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TELA Bio in a report on Tuesday, April 21st. Finally, Lake Street Capital reduced their price target on shares of TELA Bio from $3.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday, March 25th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $2.20.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC lifted its holdings in shares of TELA Bio by 161.3% in the third quarter. Citadel Advisors LLC now owns 35,281 shares of the company’s stock worth $53,000 after acquiring an additional 21,781 shares during the last quarter. Susquehanna International Group LLP grew its holdings in shares of TELA Bio by 551.2% during the 3rd quarter. Susquehanna International Group LLP now owns 85,763 shares of the company’s stock valued at $128,000 after purchasing an additional 72,594 shares during the last quarter. Renaissance Technologies LLC increased its position in TELA Bio by 101.4% during the 4th quarter. Renaissance Technologies LLC now owns 128,700 shares of the company’s stock worth $152,000 after purchasing an additional 64,800 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in TELA Bio in the 4th quarter valued at approximately $48,000. Institutional investors and hedge funds own 94.35% of the company’s stock.

TELA Bio Company Profile

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.